Clozapine in tardive dyskinesia

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Clozapine, an atypical antipsychotic, has limited clinical data in the U.S.
• Tardive dyskinesia (TD) is a potential side effect of antipsychotic treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of clozapine in chronic schizophrenic patients with TD.
• To assess the impact of clozapine on TD symptoms and its withdrawal effects.

Main Methods:

• A clinical evaluation of 12 chronic schizophrenic patients with TD.
• Administration of clozapine and monitoring for antipsychotic activity and TD symptom changes.
• Observation of adverse events, including neutropenia, convulsions, and withdrawal effects.

Main Results:

• Clozapine demonstrated antipsychotic activity and suppressed TD symptoms.
• A significant rebound of TD symptoms was observed upon clozapine withdrawal.
• Adverse events included neutropenia in two patients, one convulsion, three with marked withdrawal effects, and one hypotensive collapse with atrial fibrillation.

Conclusions:

• Clozapine shows potential for treating TD in schizophrenia.
• Significant adverse effects, particularly neutropenia, may restrict clozapine's routine clinical use.
• Further investigation in larger patient cohorts is necessary to confirm these findings.